Table 3.
Summary of the characteristics of patients who developed retinal vein occlusion after COVID-19 vaccination.
| Eye Number | Age, Years | Gender | Laterality | Underlying Disease | Underlying Ocular History |
Type of Vaccination |
Number of Vaccination |
Interval of Vaccine Inoculation to Symptom Development (Days) | Treatment | Hematologic Abnormality | Anti-PF4 Antibody | Visual Acuity before Symptom development * |
Visual Acuity at Symptom Development * |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13 | 68 | F | OS | Dyslipidemia | Vitrectomy for vitreous hemorrhage Cataract surgery |
AstraZeneca | 1 | 1 | Observation | Not tested | Not tested | - | HM |
| 14 | 76 | M | OS | HTN | NTG Cataract surgery |
Pfizer | 1 | 3 | Observation | Tested with negative result | Tested with negative result | 1 | 0.8 |
| 15 | 85 | F | OD | DM HTN ESRD Old tuberculosis Dementia |
Vitrectomy with cataract surgery for vitreous hemorrhage | Pfizer | 2 | 1 | Anti-VEGF (Bevacizumab) | Not tested | Not tested | 0.1 | FC10 |
| 16 | 59 | M | OS | DM HTN |
Vitrectomy with secondary IOL scleral fixation | AstraZeneca | 1 | 2 | Observation | Tested with negative result | Tested with negative result | 0.8 | 0.8 |
| 17 | 61 | M | OD | None | None | AstraZeneca | 1 | 2 | Anti-VEGF (Bevacizumab) | Tested with negative result | Tested with negative result | - | 0.04 |
| 18 | 79 | M | OS | DM Early gastric cancer |
None | Pfizer | 2 | 2 | Anti-VEGF (Bevacizumab) | Tested with negative result | Tested with negative result | - | 0.04 |
| 19 | 77 | F | OS | HTN HBV carrier Sigmoid colon cancer on chemotherapy s/p low anterior resection |
Cataract surgery | Pfizer | 1 | 16 | Anti-VEGF (Bevacizumab) | Not tested | Not tested | - | 0.8 |
| 20 | 63 | M | OD | DM | DME Intravitreous triamcinolone injection |
Pfizer | 1 | 13 | Anti-VEGF (Bevacizumab) | Tested with low Hb, Hct | Tested with negative result | 0.4 | 0.01 |
| 21 | 51 | F | OS | HTN | None | AstraZeneca | 1 | 21 | Anti-VEGF (Bevacizumab) | Not tested | Not tested | - | 0.09 |
| 22 | 81 | F | OS | HTN | Cataract surgery | Pfizer | 1 | 4 | Observation | Not tested | Not tested | - | 0.3 |
| 23 | 61 | M | OS | HTN | Uveitis | AstraZeneca | 1 | 3 | Observation | Not tested | Not tested | 1 | 0.9 |
AMD = age-related macular degeneration; DM = diabetes mellitus; DME = diabetic macular edema; ESRD = end-stage renal disease; F = female; HBV = hepatitis virus B; HTN = hypertension; IOL = intraocular lens; M = male; NTG = normal tension glaucoma; OD = oculus dexter; OS = oculus sinister; VEGF = vascular endothelial growth factor; * Visual acuity was demonstrated with decimal system.